Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV. Migliaccio I, et al. Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19. Breast Cancer Res Treat. 2010. PMID: 19924529 Free PMC article.
Targeting triple negative breast cancer: is p53 the answer?
Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A. Turner N, et al. Among authors: migliaccio i. Cancer Treat Rev. 2013 Aug;39(5):541-50. doi: 10.1016/j.ctrv.2012.12.001. Epub 2013 Jan 12. Cancer Treat Rev. 2013. PMID: 23321033 Review.
Adjuvant chemotherapy: which patient? What regimen?
Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Turner N, et al. Among authors: migliaccio i. Am Soc Clin Oncol Educ Book. 2013:3-8. doi: 10.14694/EdBook_AM.2013.33.3. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714442 Free article.
The continued evidence from overviews: what is the clinical utility?
Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Turner N, et al. Among authors: migliaccio i. Breast. 2013 Aug;22 Suppl 2:S8-11. doi: 10.1016/j.breast.2013.07.002. Breast. 2013. PMID: 24074798 Free article. Review.
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R. Malorni L, et al. Among authors: migliaccio i. Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10. Mol Cancer Res. 2016. PMID: 26965145 Free PMC article.
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L. Jeselsohn R, et al. Among authors: migliaccio i. Clin Cancer Res. 2016 Dec 1;22(23):5755-5764. doi: 10.1158/1078-0432.CCR-16-0148. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185372 Free PMC article. Clinical Trial.
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A, Migliaccio I. Malorni L, et al. Among authors: migliaccio i. Oncotarget. 2016 Sep 13;7(42):68012-68022. doi: 10.18632/oncotarget.12010. Oncotarget. 2016. PMID: 27634906 Free PMC article.
57 results